Corvus Pharmaceuticals Inc. (CRVS) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 39.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CRVS currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.94) and Max Pain ($10.74) forces dealer call-delta covering toward $28.30.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Corvus Pharmaceuticals Inc. (CRVS) dropped -2.76% to $10.23, trading at 19% of its 52-week range ($6.39 – $26.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRVS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRVS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Corvus Pharmaceuticals Inc. (CRVS) ranks #912 by composite RQD confidence (31/100, grade E) and #380 by equity capitalization ($860.6M). Within this direct 5-issuer industry benchmark cohort, CRVS leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CRVS at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRVS
ACTIVE
Corvus Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -2.76% | $860.6M | Benchmark Subject |
| PHAR Pharming Group N.V. ADS each representing 10 | D+ | 58/100 | — | — | — | -1.06% | $856.7M | /phar-vs-crvs → |
| IVA Inventiva S.A. American Depository Shares | C- | 61/100 | — | — | — | +0.54% | $881.3M | /iva-vs-crvs → |
| ALMS Alumis Inc. | E | 23/100 | — | — | -35.0% | -3.37% | $891.8M | /alms-vs-crvs → |
| OBX Obsidian Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.48% | $896.9M | /obx-vs-crvs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corvus Pharmaceuticals Inc. (CRVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.3M, operating cash flow of -$32.8M, and free cash flow of -$33.0M (-29.7% YoY). On the balance sheet, CRVS closed FY2025 with $71.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$15.3M | -$32.8M | -$33.0M | $71.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$62.3M | -$25.4M | -$25.4M | $68.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$27.0M | -$23.9M | -$23.9M | — | — |
As of 2026-11-01, Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.23 (-2.76% 1D, market cap $860.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVS ranks #912 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVS carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $856.7M) and IVA (Inventiva S.A. American Depository Shares) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, CRVS leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).
Per CRVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626971), Corvus Pharmaceuticals Inc. generated $0 in revenue, -$15.3M in net income, and -$33.0M in free cash flow against $71.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRVS last traded at $10.23 (-2.76% on volume of 852,696 shares), positioning the stock -14.32% below its 50-day simple moving average ($11.94) and -29.16% below its 200-day simple moving average ($14.44). Across its 52-week range of $6.39 to $26.95, CRVS sits at the 18.7% percentile with a 14-day RSI of 39.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($8.97 to $11.49).
Why CRVS Stock dropped -2.76% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.